Of the 23 analysts covering BioMarin Pharmaceutical (BMRN) in September, 19 of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for BioMarin stock is 1.78 with a target price of $119.35, implying an upside potential of 21.1% over its closing price of $98.58 on September 12.
In early 2018, amid the broader market turmoil, BioMarin stock corrected from $92.39 on January 23 to $77.67 on March 1. Subsequently, it steadily climbed to $105.72 on August 7 and then sharply corrected to its current $98 level in September.
The enterprise value of BioMarin is $17.24 billion, and its enterprise-value-to-revenue ratio is 11.98x. Its price-to-sales ratio is 12.17x, and its price-to-book ratio is 6.13x.
Its current ratio, a metric of how effectively a company can meet its short-term obligations, stands at 2.80x. In comparison, the current ratios of peers Voyager Therapeutics (VYGR), Nightstar Therapeutics (NITE), and Audentes Therapeutics (BOLD) are 6.90x, 9.90x, and 19.10x, respectively.
We’ll take a look at Solid Biosciences’ research pipeline in the next part.